Search research articles
Contact Us
Filters
Showing results (21-30 of 42) with videos related to
Page
of 5
Sort By:
British Journal of Clinical Pharmacology
|
June 25, 2010
Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy
Christa E Nath, Peter J Shaw, Judith Trotman, et al.
Bone Marrow Research
|
November 3, 2011
Factors influencing the abundance of the side population in a human myeloma cell line
Sui-Lin Mo, Jia Li, Yen S Loh, et al.
Leukemia & Lymphoma
|
February 20, 2019
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study
Noemi Horvath, Andrew Spencer, Melita Kenealy, et al.
Internal Medicine Journal
|
January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Shirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
Immunology and Cell Biology
|
January 22, 2016
A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset
Christian Bryant, Phillip D Fromm, Fiona Kupresanin, et al.
European Journal of Haematology
|
July 3, 2024
A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies
Eric Wenlong Li, Esther Jones, Christian Bryant, et al.
The Lancet. Oncology
|
August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
Frontiers in Immunology
|
August 21, 2019
Mass Cytometry Discovers Two Discrete Subsets of CD39<sup>-</sup>Treg Which Discriminate MGUS From Multiple Myeloma
Felix Marsh-Wakefield, Annabel Kruzins, Helen M McGuire, et al.
Internal Medicine Journal
|
March 7, 2023
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia
Shirlene Sim, Anna Kalff, Gina Tuch, et al.
Ejhaem
|
July 18, 2022
Alcohol and tobacco use and risk of multiple myeloma: A case-control study
Simon Cheah, Julie K Bassett, Fiona J Bruinsma, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 42) with videos related to
Sort By:
Page
of 5
British Journal of Clinical Pharmacology
|
June 25, 2010
Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy
Christa E Nath, Peter J Shaw, Judith Trotman, et al.
Bone Marrow Research
|
November 3, 2011
Factors influencing the abundance of the side population in a human myeloma cell line
Sui-Lin Mo, Jia Li, Yen S Loh, et al.
Leukemia & Lymphoma
|
February 20, 2019
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study
Noemi Horvath, Andrew Spencer, Melita Kenealy, et al.
Internal Medicine Journal
|
January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Shirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
Immunology and Cell Biology
|
January 22, 2016
A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset
Christian Bryant, Phillip D Fromm, Fiona Kupresanin, et al.
European Journal of Haematology
|
July 3, 2024
A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies
Eric Wenlong Li, Esther Jones, Christian Bryant, et al.
The Lancet. Oncology
|
August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
Frontiers in Immunology
|
August 21, 2019
Mass Cytometry Discovers Two Discrete Subsets of CD39<sup>-</sup>Treg Which Discriminate MGUS From Multiple Myeloma
Felix Marsh-Wakefield, Annabel Kruzins, Helen M McGuire, et al.
Internal Medicine Journal
|
March 7, 2023
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia
Shirlene Sim, Anna Kalff, Gina Tuch, et al.
Ejhaem
|
July 18, 2022
Alcohol and tobacco use and risk of multiple myeloma: A case-control study
Simon Cheah, Julie K Bassett, Fiona J Bruinsma, et al.
Page
of 5